NanoLoom
NanoLoom is an advanced imaging-based drug discovery platform designed to transform how DNA-protein interactions are analyzed at the single-molecule level. By combining microfluidics, nanotechnology, and AI-driven data analysis, this platform enables high-through put visualization and interpretation of molecular dynamics that were previously difficult to observe in real time. Developed through an international collaboration between technology and research partners, it bridges the gap between academic molecular research and industrial drug development pipelines.
Funded by Eureka Eurostars
Features and Benefits
Traditional single-molecule methods offer high precision but lack the throughput needed for drug development. NanoLoom addresses this limitation by integrating advanced nanofabrication, microfluidic engineering, and AI-assisted analytics into a unified platform. This platform aims to reshape early-stage drug discovery by enabling scalable, high-resolution molecular analysis. It has potential applications across cancer research, infectious diseases, neurodegenerative disorders, and emerging therapeutic fields.
Microfluidic Chip
A microfluidic chip aligns thousands of DNA molecules to enable high-resolution visualization of protein behaviour. The chip leverages advanced nanoimprint lithography and molecular self-assembly to achieve scalable and cost-efficient production.
Drug Screening Workflow
The platform’s specialized workflow combines imaging and molecular analysis to study challenging drug targets, including DNA-binding proteins that are often considered difficult to analyze with conventional approaches.
AI-Assisted Data Analysis and Automated Workflows
An integrated analytics suite processes large imaging datasets, extracts kinetic parameters, and supports automated identification of relevant molecular activity. Together, these components form a comprehensive platform for next-generation drug discovery and molecular research. Direct imaging and AI-supported analytics reduce false positives and provide deeper insights into mechanisms of action.
Accelerated Drug Development
NanoLoom enables faster identification of drug candidates by allowing simultaneous observation of thousands of molecular interactions, significantly reducing early-stage research time.
Bridging Research and Industry
The platform supports both academic research environments and pharmaceutical workflows, enabling smoother technology transfer from laboratory discovery to clinical innovation.
Cost Efficiency
By improving screening accuracy and automation, NanoLoom helps reduce experimental complexity and overall R&D costs.
Benefits for Patients:
NanoLoom accelerates drug discovery, enabling faster access to innovative therapies for complex diseases such as neurodegenerative disorders. By improving the precision of early-stage drug validation, it supports the development of safer and more effective treatments. This can ultimately lead to better clinical outcomes and improved quality of life.
Benefits for Health Professionals:
This innovative platform generates high-quality mechanistic data that enhances confidence in new therapeutic approaches. Its precise molecular insights reduce uncertainty around drug mechanisms and potential efficacy. This supports more informed treatment decisions and improved patient care.
Benefits for Healthcare Systems, Providers and Authorities:
By identifying ineffective drug candidates earlier in development, the system reduces R&D risk. This improves resource allocation and lowers long-term drug development costs. As a result, it contributes to more sustainable healthcare systems and stronger evidence for regulatory evaluation.